Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pimasertib + TAK-632 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pimasertib | AS703026|MSC1936369B | MEK inhibitor (Pan) 27 MEK1 Inhibitor 27 MEK2 Inhibitor 25 | Pimasertib (MSC1936369B) binds to and inhibits MEK1/2, preventing activation of downstream targets and potentially reducing tumor cell proliferation (PMID: 23587417, PMID: 31870556). | |
| TAK-632 | TAK 632|TAK632 | RAF Inhibitor (Pan) 29 | TAK-632 is an inhibitor of Raf, which has been shown to suppress the kinase activity of the Raf dimer thereby resulting in diminished paradoxical activation of Raf (PMID: 24121489, PMID: 31734178). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|